Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Latest Advances in PDX Modelling for Oncology Drug Discovery

Published: Friday, September 13, 2013
Last Updated: Friday, September 13, 2013
Bookmark and Share
PRECOS' co-presentation with Crown Bioscience from Tumor Models Boston 2013 meeting available for download.

Preclinical Oncology Services Limited (PRECOS) has announced the availability of its co-presentation with Crown Bioscience delivered at the Tumor Models Boston 2013 meeting.

The presentation highlights the application of human surrogate trials to oncology drug discovery and how a comprehensive panel of PDX (Patient-Derived Xenograft) models of cancer can help better predict the effectiveness of drugs in clinical trials.

Historically the oncology drug development process is slow, expensive, inefficient and ultimately unsustainable. PRECOS and Crown Bioscience recognize the need to bring clinical decision-making earlier into the process.

Dr Aaron Cranston, Head of in vivo services, PRECOS Ltd comments, “Translating oncology drug discovery into improved patient outcome is the fundamental mission for both PRECOS and Crown Biosciences. By using human surrogate trials (HuTrials®) it is possible to identify biomarker signatures of patient responders and non-responders following treatment with targeted agents, reduce the attrition rate of new chemical entities (NCEs) in the clinic, accelerating drug development and improve chances of translational success.

By focusing on developing tumor models that are truly representative of patient outcomes, PRECOS and Crown Biosciences enable drug developers to overcome the challenges faced in preclinical oncology when testing new cancer drugs.

Problems in oncology drug development include a failure to consistently deliver highly effective drugs to patients, with many new drugs providing incremental benefit at non-incremental costs.

The ultimate goal in the oncology community is effective drug performance in the clinic and PDX models are superior in predicting efficacy and mimicking tumour activity in patients.

Also known as tumor graft models, PDXs are based on the transfer of primary tumors directly from the patient into an immunodeficient mouse.

PRECOS presented alongside its parent company Crown Bioscience on the latest developments in PDX modelling, highlighting the scale and skill of Crown Bioscience’s resources to maintain hundreds of in vivo PDX models in simultaneous passage ready for screening.

The presentation illustrates how PDX are being used today to discover biomarkers and run human surrogate trials using the world’s most comprehensive commercially available PDX collection.

The presentation is available to download via www.precos.co.uk/publications/ or email precos@scottpr.com to request a copy.

Dr Cranston continues, “PRECOS is committed to developing improved preclinical models and providing researchers with the very best oncology tools for superior predictions, which will ultimately lead to enhanced patient response. Molecular profiling and characterization underpins the models and the innovative approaches developed by PRECOS enable scientists to fast-track new agents into the clinic.”

Tumor Models 2013 was hosted in Boston from 23rd - 25th July. The meeting was attended by international researchers interested in optimizing models, exploring alternatives and predicting efficacy for enhanced clinical performance.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PRECOS Appoints Dr Martin Page as Scientific Consultant
Appointment reinforces the ambition of PRECOS to contribute to the growing cancer therapy market.
Tuesday, February 21, 2012
PRECOS and Argenta Extend Collaboration to Offer World Class Integrated Oncology Drug Discovery Services
Five-year extension of the alliance allows both companies to offer unrivalled expertise in cancer research to their pharmaceutical clients.
Wednesday, March 23, 2011
PRECOS Secures Multi Year Global Service Agreement with Leading Pharmaceutical Company
PRECOS to provide clinical expertise to support Janssen’s oncology drug discovery, development and biomarker programmes.
Tuesday, November 23, 2010
Scientific News
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!